

# Michele Aieta

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2149224/michele-aieta-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

99  
papers

2,235  
citations

26  
h-index

44  
g-index

107  
ext. papers

2,639  
ext. citations

4.2  
avg, IF

4.33  
L-index

#	Paper	IF	Citations
99	Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. <i>Annals of Oncology</i> , <b>2009</b> , 20, 1535-1542	10.3	155
98	Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 713-21	21.7	131
97	Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 4469-74	2.2	114
96	M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by CellSearch analysis. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 5233-43	12.9	110
95	Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone. <i>Frontiers in Pharmacology</i> , <b>2016</b> , 7, 376	5.6	93
94	Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. <i>Oncotarget</i> , <b>2016</b> , 7, 54564-54571	3.3	89
93	Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. <i>Annals of Oncology</i> , <b>2018</b> , 29, 2328-2333	10.3	77
92	Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. <i>BJU International</i> , <b>2011</b> , 107, 234-9	5.6	71
91	Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. <i>European Urology</i> , <b>2015</b> , 68, 147-53	10.2	62
90	Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies. <i>Critical Reviews in Oncology/Hematology</i> , <b>2014</b> , 92, 11-24	7	60
89	Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study. <i>Advances in Therapy</i> , <b>2020</b> , 37, 1145-1155	4.1	52
88	Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study. <i>Cancer</i> , <b>2014</b> , 120, 2457-63	6.4	52
87	Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor. <i>European Urology</i> , <b>2006</b> , 50, 1032-8; discussion 1038-9	10.2	51
86	Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. <i>Annals of Oncology</i> , <b>2016</b> , 27, 1055-1061	10.3	49
85	Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis. <i>Future Oncology</i> , <b>2019</b> , 15, 2423-2433	3.6	48
84	Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. <i>European Urology</i> , <b>2010</b> , 58, 906-11	10.2	48
83	Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. <i>BJU International</i> , <b>2012</b> , 110, E661-6	5.6	47

82	Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to sunitinib in metastatic renal cancer. <i>British Journal of Cancer</i> , <b>2012</b> , 107, 1286-94	8.7	46
81	Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib. <i>Lung Cancer</i> , <b>2013</b> , 81, 328-336	5.9	45
80	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology</i> , <b>2018</b> , 19, 474-485	21.7	39
79	Carcinogenesis of pancreatic adenocarcinoma: precursor lesions. <i>International Journal of Molecular Sciences</i> , <b>2013</b> , 14, 19731-62	6.3	39
78	The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy. <i>Critical Reviews in Oncology/Hematology</i> , <b>2013</b> , 86, 42-51	7	36
77	Evaluation of Social Support, Quality of Life, and Body Image in Women with Breast Cancer. <i>Breast Care</i> , <b>2016</b> , 11, 28-32	2.4	32
76	Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study primary analysis of 2573 patients. <i>European Journal of Cancer</i> , <b>2017</b> , 82, 237-246	7.5	30
75	Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation. <i>Journal of Proteome Research</i> , <b>2011</b> , 10, 3089-97	5.6	30
74	Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , <b>2013</b> , 9, 889-97	3.6	27
73	Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management. <i>Future Oncology</i> , <b>2015</b> , 11, 2043-8	3.6	26
72	Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey. <i>PLoS ONE</i> , <b>2014</b> , 9, e105268	3.7	25
71	9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 501-501	2.2	23
70	Progress and challenges in the treatment of small cell lung cancer. <i>Medical Oncology</i> , <b>2017</b> , 34, 110	3.7	22
69	Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients. <i>Future Oncology</i> , <b>2014</b> , 10, 1353-60	3.6	21
68	Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer. <i>Journal of Geriatric Oncology</i> , <b>2014</b> , 5, 156-63	3.6	21
67	Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience. <i>European Journal of Clinical Pharmacology</i> , <b>2012</b> , 68, 505-12	2.8	20
66	A pilot characterization of human lung NSCLC by protein pathway activation mapping. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 1755-1766	8.9	19
65	Monitoring and Characterization of Circulating Tumor Cells (CTCs) in a Patient With EML4-ALK-Positive Non-Small Cell Lung Cancer (NSCLC). <i>Clinical Lung Cancer</i> , <b>2016</b> , 17, e173-e177	4.9	19

64	Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis. <i>Clinical Genitourinary Cancer</i> , <b>2014</b> , 12, 182-9	3.3	18
63	Circulating tumor cells: utopia or reality?. <i>Future Oncology</i> , <b>2013</b> , 9, 1337-52	3.6	17
62	Poor survival in prostate cancer patients with primary refractoriness to docetaxel. <i>European Urology</i> , <b>2014</b> , 65, 505-7	10.2	17
61	Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with Cisplatin-refractory germ cell tumor: preliminary experience. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2004</b> , 27, 457-60	2.7	17
60	The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review. <i>Expert Opinion on Biological Therapy</i> , <b>2016</b> , 16, 1387-1401	5.4	16
59	Selected case from the Arkadi M. Rywlin International Pathology Slide Series: Leiomyomatosis peritonealis disseminata: report of 3 cases with extensive review of the literature. <i>Advances in Anatomic Pathology</i> , <b>2014</b> , 21, 201-15	5.1	15
58	Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer. <i>Investigational New Drugs</i> , <b>2018</b> , 36, 1133-1137	4.3	14
57	Metabolic syndrome as a peculiar target for management of prostate cancer patients. <i>Clinical Genitourinary Cancer</i> , <b>2013</b> , 11, 211-20	3.3	14
56	Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry. <i>Bone Marrow Transplantation</i> , <b>2013</b> , 48, 414-8	4.4	14
55	Possible applications of circulating tumor cells in patients with non small cell lung cancer. <i>Lung Cancer</i> , <b>2017</b> , 107, 59-64	5.9	13
54	TRAP1 protein signature predicts outcome in human metastatic colorectal carcinoma. <i>Oncotarget</i> , <b>2017</b> , 8, 21229-21240	3.3	13
53	Long-term survival in small cell lung cancer: a case report and review of the literature. <i>Future Oncology</i> , <b>2014</b> , 10, 523-8	3.6	11
52	Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer. <i>Oncotarget</i> , <b>2018</b> , 9, 22332-22339	3.3	11
51	Anal metastasis from breast cancer: a case report and review of the literature. <i>Future Oncology</i> , <b>2012</b> , 8, 333-6	3.6	10
50	Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma. <i>Medical Oncology</i> , <b>2018</b> , 35, 28	3.7	9
49	The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale). <i>BMC Cancer</i> , <b>2018</b> , 18, 552	4.8	9
48	Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 7281-8	5.6	8
47	Focus on lung cancer screening. <i>Journal of Thoracic Disease</i> , <b>2020</b> , 12, 3815-3820	2.6	8

46	Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study. <i>Medicine (United States)</i> , <b>2018</b> , 97, e10745	1.8	8
45	Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results. <i>Journal of Translational Medicine</i> , <b>2019</b> , 17, 296	8.5	7
44	Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: results from the Italian national registry. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 501-6	4.7	7
43	Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone. <i>Investigational New Drugs</i> , <b>2018</b> , 36, 1110-1115	4.3	7
42	Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 265.e15-21	2.8	6
41	Liquid biopsy for monitoring anaplastic lymphoma kinase inhibitors in non-small cell lung cancer: two cases compared. <i>Journal of Thoracic Disease</i> , <b>2017</b> , 9, S1391-S1396	2.6	6
40	Lenvatinib for the treatment of renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , <b>2018</b> , 27, 507-512	5.9	6
39	Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. <i>Future Oncology</i> , <b>2016</b> , 12, 493-502	3.6	6
38	Pyrosequencing evaluation of low-frequency KRAS mutant alleles for EGF receptor therapy selection in metastatic colorectal carcinoma. <i>Future Oncology</i> , <b>2014</b> , 10, 713-23	3.6	6
37	The clinical impact of a cardiologic follow-up in breast cancer survivors: an observational study. <i>International Journal of Immunopathology and Pharmacology</i> , <b>2010</b> , 23, 1221-7	3	6
36	Treatment of performance status 2 patients with advanced non-small-cell lung cancer: what we know and what we don't know. <i>Future Oncology</i> , <b>2009</b> , 5, 837-41	3.6	6
35	Somatostatin Analog Therapy in Small Cell Lung Cancer. <i>Seminars in Nuclear Medicine</i> , <b>2016</b> , 46, 239-42	5.4	6
34	Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223. <i>OncoTargets and Therapy</i> , <b>2019</b> , 12, 9-13	4.4	6
33	When crizotinib-induced bradycardia becomes symptomatic: role of concomitant drugs. <i>Expert Review of Anticancer Therapy</i> , <b>2015</b> , 15, 761-3	3.5	5
32	Relationship of serum lactate dehydrogenase level with first remission length in adult acute lymphocytic leukaemia. <i>British Journal of Haematology</i> , <b>1987</b> , 66, 49-53	4.5	5
31	Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone. <i>Prostate</i> , <b>2017</b> , 77, 1012-1019	4.2	4
30	Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?. <i>Medical Oncology</i> , <b>2014</b> , 31, 78	3.7	4
29	Identification of a new insertion in exon 20 of EGFR in a woman with NSCLC. <i>Medical Oncology</i> , <b>2012</b> , 29, 3198-201	3.7	4

28	Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer. <i>Scientific Reports</i> , <b>2020</b> , 10, 19281	4.9	4
27	Is there a role for immunotherapy in malignant pleural mesothelioma?. <i>Medical Oncology</i> , <b>2018</b> , 35, 98	3.7	4
26	Molecular characterization and prognostic significance of circulating tumor cells in patients with non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , <b>2017</b> , 9, S1359-S1363	2.6	3
25	Evaluation of molecular prognostic and predictive factors: an important step towards personalised treatment in non small cell lung cancer. <i>Medical Oncology</i> , <b>2012</b> , 29, 1599-605	3.7	3
24	Prognostic role of circulating tumor cells-CTCs in metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4568-4568	2.2	3
23	Gene Copy Number and Post-Transductional Mechanisms Regulate TRAP1 Expression in Human Colorectal Carcinomas. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 21,	6.3	3
22	Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial. <i>Oncologist</i> , <b>2021</b> , 26, 740-750	5.7	3
21	A fully automated assay to detect the expression of pan-cytokeratins and of EML4-ALK fusion protein in circulating tumour cells (CTCs) predicts outcome of non-small cell lung cancer (NSCLC) patients. <i>Translational Lung Cancer Research</i> , <b>2021</b> , 10, 80-92	4.4	3
20	The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer. <i>Investigational New Drugs</i> , <b>2019</b> , 37, 524-530	4.3	2
19	Association between neutropenia and response to ramucirumab and paclitaxel in patients with metastatic gastric cancer. <i>Anti-Cancer Drugs</i> , <b>2020</b> , 31, 632-636	2.4	2
18	Everolimus in combination with octreotide LAR as the first-line treatment for advanced neuroendocrine tumors: A phase II trial of the I.T.M.O. (Italian Trials in Medical Oncology) group.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4136-4136	2.2	2
17	Clinical outcomes of patients (pts) age 80 or older treated with docetaxel (DOC) as first-line chemotherapy for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (DELPHI study).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 92-92	2.2	2
16	Poor outcome for patients with gastric cancer and lung metastases treated with ramucirumab and paclitaxel. <i>Anti-Cancer Drugs</i> , <b>2019</b> , 30, e0789	2.4	2
15	Influence of Age and the Gleason Score in the Choice of Novel Hormonal Therapies Before and After Chemotherapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>2019</b> , 34, 141-146	3.9	2
14	New cancer drugs: the Italian unsatisfactory solution. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1448	10.3	1
13	Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity: two cases and review of the literature. <i>Future Oncology</i> , <b>2013</b> , 9, 127-33	3.6	1
12	Reflections about off-label use of anticancer drugs. <i>Therapeutic Drug Monitoring</i> , <b>2012</b> , 34, 604	3.2	1
11	Salvage Treatment with Epirubicin and/or Paclitaxel in Metastatic Breast Cancer Patients Relapsed after High-dose Chemotherapy with Peripheral Blood Progenitor Cells. <i>Tumori</i> , <b>2001</b> , 87, 134-137	1.7	1

10	Impact of new agents (NAs) on post-docetaxel (DOC) survival of octogenarians with metastatic castration resistant prostate cancer (mCRPC) patients (pts): Results of an Italian multicenter retrospective study (DELPHI study).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e16017-e16017	2.2	1
9	Systemic immune-inflammation index to predict the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 547-547	2.2	1
8	Therapeutic management of a symptomatic Kaposi's sarcoma patient with renal failure undergoing haemodialysis: A case report.. <i>Dermatology Reports</i> , <b>2022</b> , 14, 9113	0.9	0
7	Lower urinary tract infections from external beam radiation therapy in prostate cancer: A single institution experience. <i>Reports of Practical Oncology and Radiotherapy</i> , <b>2018</b> , 23, 298-299	1.5	
6	Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer?. <i>Medicine (United States)</i> , <b>2019</b> , 98, e16249	1.8	
5	Role and limits of salvage chemotherapy in breast cancer patients treated with high-dose chemotherapy. <i>Annals of Oncology</i> , <b>2003</b> , 14, 1794-5	10.3	
4	Randomized, multicentre phase II trial of the sequencing of radium-223 and docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS396-TPS396	2.2	
3	A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 5050-5050	2.2	
2	Phase II study of everolimus in combination with octreotide LAR in first line setting for patients with neuroendocrine tumors (I.T.M.O. study): A 4-year update.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e15199-e15199	2.2	
1	Clinical outcomes of patients (pts) age 60 or younger treated with docetaxel (DOC) for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (CYCLOP study).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 214-214	2.2	